BabyBreathe干预对维持产后戒烟的有效性:多中心实用性随机对照试验
该多中心实用性随机对照试验纳入887名在孕前12个月内或孕期戒烟、并经呼出气一氧化碳验证的孕妇,1:1随机接受BabyBreathe干预或常规产后护理。BabyBreathe包括孕28-32周及产后10-14天的人际支持、邮寄盒子(含戒烟维持建议、尼古丁替代口香糖样本、激励工具)、定制短信、网站与应用。主要终点产后12个月经呼出气一氧化碳≤7 ppm验证的持续戒烟率两组无显著差异(54.9% vs 49.9%,OR 1.23,95%CI 0.94-1.60,P=0.13)。事后符合方案分析显示干预组优于常规护理(57.6% vs 49.9%,调整OR 1.36,95%CI 1.02-1.81,P=0.04)。
要点
- 产后12个月持续戒烟率BabyBreathe组54.9%(242/441)vs 常规护理组49.9%(222/445),OR 1.23(95%CI 0.94-1.60),P=0.13,未达统计学显著。
- 风险差4.8%(95%CI -1.7%至11.2%),NNT 21(获益NNT 8.9至∞,受害NNT 59)。
- 事后符合方案分析中,仅纳入按计划接受人际支持者,BabyBreathe组57.6%(200/347)vs 常规护理组49.9%(222/445),调整OR 1.36(95%CI 1.02-1.81),P=0.04,风险差7.2%(0.3%-14.1%),NNT 13.9(7.1-333.3)。
- 无试验相关不良事件发生。
- 作者认为,关注干预保真度及将BabyBreathe进一步针对低社会经济地位群体可能是有必要的。
适用人群与场景
- 英国社区健康访视服务中招募的孕妇及在孕前12个月内或孕期报告戒烟、并经呼出气一氧化碳验证戒烟的个体。
诊断标准与关键阈值
- 主要终点持续戒烟定义为产后12个月呼出气一氧化碳浓度≤7 ppm。
处置流程与药物剂量
- BabyBreathe干预包括:孕28-32周及产后10-14天提供面对面或远程戒烟维持人际支持;出生通知时邮寄BabyBreathe盒子,内含戒烟维持的理论指导建议、尼古丁替代口香糖样本和激励工具;提供定制激励与教育短信;网站和应用提供定制戒烟维持建议、社会支持、激励工具和游戏化功能。
- 对照组接受常规产后护理。
研究设计与关键结果
- 多中心实用性个体随机对照试验,887名参与者随机(BabyBreathe组442例,常规护理组445例),排除1例随机后病例,886例纳入意向性治疗分析。
- 主要终点产后12个月持续戒烟率:BabyBreathe组54.9%(242/441)vs 常规护理组49.9%(222/445),OR 1.23(95%CI 0.94-1.60),P=0.13,风险差4.8%(-1.7%至11.2%),NNT 21(获益NNT 8.9至∞,受害NNT 59),组间差异未达统计学显著。
- 事后符合方案分析:BabyBreathe组57.6%(200/347)vs 常规护理组49.9%(222/445),调整OR 1.36(95%CI 1.02-1.81),P=0.04,风险差7.2%(0.3%-14.1%),NNT 13.9(7.1-333.3)。
- 无试验相关不良事件发生。
证据类型、等级与局限
- 多中心实用性个体随机对照试验,非盲法设计。
- 主要终点意向性治疗分析未达统计学显著;事后符合方案分析显示统计学显著获益。
- 局限:主要分析未达统计学显著;获益仅在事后符合方案分析中观察到。
对床旁实践的改变
- 对于在孕前或孕期戒烟者,BabyBreathe干预未显著提高产后12个月持续戒烟率,不能据此常规推荐该干预用于维持产后戒烟。
- 事后符合方案分析提示,在按计划接受人际支持的个体中BabyBreathe可能优于常规护理,作者认为关注干预保真度及将BabyBreathe进一步针对低社会经济地位群体可能是有必要的。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To assess the effectiveness of an interpersonal and digital intervention, BabyBreathe, for maintaining postpartum smoking cessation.
DESIGN: Multicentre pragmatic individually randomised controlled trial.
SETTING: Community health visiting services in the UK.
PARTICIPANTS: 887 pregnant women and people who reported quitting smoking in the 12 months before, or during, pregnancy, with abstinence verified by exhaled carbon monoxide readings. A secure web based randomisation sequence, stratified by recruitment hub, partner smoking status, and quit timing (before or during pregnancy), was used to randomise participants (1:1) to receive the intervention or usual care. The trial was unblinded.
INTERVENTION: BabyBreathe comprised in-person or remote smoking cessation maintenance interpersonal support at 28-32 weeks' gestation and 10-14 days post partum. The BabyBreathe box, posted at the time of birth notification, contained theory driven advice for cessation maintenance, a sample of nicotine replacement gum, and motivational tools. Tailored motivational and educational text messages were provided. A website and app provided tailored cessation maintenance advice, social support, motivational tools, and gamification. Control was usual postpartum care.
MAIN OUTCOME MEASURE: The primary outcome was continuous smoking abstinence, verified by exhaled carbon monoxide concentration (≤7 parts per million (ppm)) 12 months post partum.
RESULTS: Between 4 September 2021 and 3 August 2023, 887 participants were randomised: 442 to receive BabyBreathe and 445 to receive usual care. After one post-randomisation exclusion, 886 participants were included in an intention-to-treat analysis. The group difference in smoking abstinence at 12 months post partum was not significant (BabyBreathe 242/441 (54.9%) v usual care 222/445 (49.9%); odds ratio 1.23, 95% confidence interval (CI) 0.94 to 1.60, P=0.13, risk difference 4.8% (-1.7% to 11.2%), and number needed to treat (NNT) 21 (NNT to benefit 8.9 to ∞) and NNT to harm 59). A post hoc per protocol analysis favoured the intervention (BabyBreathe 200/347 (57.6%) v usual care 222/445 (49.9%); adjusted odds ratio 1.36, 95% CI 1.02 to 1.81, P=0.04), risk difference 7.2% (0.3% to 14.1%), and NNT 13.9 (7.1 to 333.3). No trial related adverse incidents occurred.
CONCLUSIONS: BabyBreathe did not statistically significantly increase sustained smoking abstinence post partum for people who quit smoking in pregnancy. A post hoc per protocol analysis, including only those who received interpersonal support as intended, showed statistically significantly greater benefit from BabyBreathe over usual care. A focus on fidelity and further targeting of BabyBreathe to groups with lower socioeconomic status may be warranted.
TRIAL REGISTRATION: ISRCTN Registry ISRCTN70307341.
参考来源
- Notley C, Belderson P, Clark L, et al. Effectiveness of the BabyBreathe intervention for maintaining postpartum smoking cessation: multicentre pragmatic randomised controlled trial. BMJ. 2026. PMID: 42613086. doi:10.1136/bmj-2026-100242
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。